Spyre Therapeutics, Inc. (SYRE) Stock
5 of the hedge funds AlphaScala tracks reported SYRE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $88.04M. Company insiders reported 0 open-market buys and 31 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which hedge funds own SYRE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 992K | $88.04M | +612% |
| Millennium Management Israel Englander | 197K | $17.46M | +34% |
| Blackstone | 120K | $10.67M | -59% |
| Citadel Ken Griffin | 103K | $9.15M | -5% |
| D.E. Shaw David Shaw | 26K | $2.35M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Spyre Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Burrows Scott L | Chief Financial Officer | SELL | 600 | $53K |
| Oct 1, 26 | Burrows Scott L | Chief Financial Officer | SELL | 1.5K | $135K |
| Oct 1, 26 | Burrows Scott L | Chief Financial Officer | SELL | 2.1K | $193K |
| Oct 1, 26 | Burrows Scott L | Chief Financial Officer | SELL | 3.1K | $285K |
| Oct 1, 26 | Burrows Scott L | Chief Financial Officer | SELL | 229 | $21K |
| Oct 1, 26 | Turtle Cameron | Chief Executive Officer | SELL | 600 | $53K |
| Oct 1, 26 | Turtle Cameron | Chief Executive Officer | SELL | 2.7K | $242K |
| Oct 1, 26 | Turtle Cameron | Chief Executive Officer | SELL | 2.6K | $241K |
| Oct 1, 26 | Turtle Cameron | Chief Executive Officer | SELL | 4.0K | $368K |
| Oct 1, 26 | Turtle Cameron | Chief Executive Officer | SELL | 5.0K | $466K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →SYRE price chart
Powered by TradingViewWhat does Spyre Therapeutics, Inc. do?
Spyre Therapeutics Inc. operates as a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Its primary function is to research and bring to market novel medicines that target the underlying causes of these conditions, improving patient outcomes and quality of life. Spyre Therapeutics is actively involved in the biotechnology sector, where it leads efforts in drug discovery and development, leveraging cutting-edge technologies to identify new therapeutic pathways. The company's pipeline includes a range of biologic and small molecule drugs, each designed to address specific immune system dysregulations. In the financial market, Spyre Therapeutics plays a crucial role as a potential driver of growth within the biotech industry, attracting attention from investors interested in companies with promising research and development capabilities. The company's advancements can lead to significant healthcare impacts, offering progressive treatments in areas of significant unmet medical need.